ImmuCell Corporation (ICCC)vsJohnson & Johnson (JNJ)
ICCC
ImmuCell Corporation
$9.95
-4.05%
HEALTHCARE · Cap: $94.18M
JNJ
Johnson & Johnson
$272.65
-1.45%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 323725% more annual revenue ($99.33B vs $30.68M). JNJ leads profitability with a 16.2% profit margin vs 2.6%. JNJ trades at a lower P/E of 41.5x. JNJ earns a higher WallStSmart Score of 54/100 (C-).
ICCC
Hold45
out of 100
Grade: D
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.2%
Fair Value
$17.65
Current Price
$9.95
$7.70 discount
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$272.65
$128.37 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 259.9% YoY
Reasonable price relative to book value
Strong operational efficiency at 26.9%
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
2.6% margin — thin
Premium valuation, high expectations priced in
Trading at 8.0x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCC
The strongest argument for ICCC centers on EPS Growth, Price/Book, Operating Margin. Revenue growth of 11.5% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Profit Margin. A P/E of 148.1x leaves little room for execution misses. Thin 2.6% margins leave little buffer for downturns.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
ICCC profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
ICCC carries more volatility with a beta of 0.62 — expect wider price swings.
ICCC is growing revenue faster at 11.5% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 45/100), backed by strong 16.2% margins. ICCC offers better value entry with a 63.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?